Overview
This is a multi-center, randomized, double blind, placebo-controlled study to evaluate the efficacy, safety, tolerance, pharmacokinetics, pharmacodynamics, and immunogenicity of CM326 in moderate-severe atopic dermatitis subjects.
Description
The study consists of 3 periods, a up-to-4-week Screening Period, a 52-week Treatment Period and a 8-week Safety Follow-up Period.
Eligibility
Inclusion Criteria:
- With confirmed Atopic Dermatitis (AD) at the screening.
- Age ≥ 18 years and ≤ 75 years, male or female.
- Have the ability to understand the nature of the study and voluntarily sign the informed consent.
- Be able to communicate well with investigators and follow up protocol requirements.
Exclusion Criteria:
- Not enough washing-out period for previous therapy.
- Received allergen specific immunotherapy (desensitization) within 6 months prior to baseline.
- Major surgery is planned during the study period.
- Women who are pregnant or breastfeeding, or who plan to become pregnant during the study.